International Journal of Management Technology and Social Sciences,
Год журнала:
2025,
Номер
unknown, С. 17 - 44
Опубликована: Янв. 30, 2025
Purpose:
The
purpose
of
this
research
is
to
explore
how
Orange,
a
powerful
information
extraction
and
predictive
modeling
software,
can
be
applied
in
the
pharmaceutical
industry
assess
visualize
effectiveness
cancer
prevention
medicines.
By
focusing
on
companies
like
Genentech
Inc.
(USA),
AstraZeneca
Pharmaceutical
PLC
(UK),
Boehringer
Ingelheim
(Germany),
Chugai
Co.
Ltd.
(Japan),
study
seeks
evaluate
which
cancer-preventing
drugs
from
these
provide
best
efficacy
while
minimizing
side
effects
for
patients.
goal
assist
healthcare
professionals
(doctors
pharmacists)
making
informed
decisions
about
most
suitable
medications
prevention,
ensuring
patient
safety
optimal
treatment
outcomes.
Design/Methodology/Approach:
This
utilizes
Orange
software’s
machine
learning
data
visualization
tools,
specifically
scatterplot
graphs,
analyze
complex
datasets
related
drugs.
using
scatterplots
concurrently
examine
multiple
parameters,
such
as
Company
Name,
Drug
Class,
Medicine
Prevention
Cancer
Diseases,
Side
Effects
Percentage
aims
identify
patterns
correlations
that
help
drug
safety.
approach
involves
analyzing
relationship
between
characteristics
effects,
providing
actionable
insights
into
different
treatments
might
interact
with
health
conditions.
Findings/Results:
findings
suggest
Orange’s
visualizations
valuable
various
medicines
across
companies.
enabling
simultaneous
analysis
software
helps
are
effective
preventing
effects.
provides
clearer
understanding
characteristics,
outcomes,
supporting
data-driven
decision-making
development
practices.
Originality/Value:
originality
lies
application
mining
capabilities
relationships
within
datasets.
use
efficacy,
an
innovative
offers
richer,
more
nuanced
contributes
optimizing
choice
strategies,
ultimately
improving
therapeutic
Paper
Type:
analytical
paper
applies
techniques
focuses
tools
extract
interpret
data,
professionals.
This
review
delves
into
the
pivotal
role
of
long
non-coding
RNA
NEAT1
in
cancer
biology,
particularly
lung
(LC).
It
emphasizes
NEAT1's
unique
subcellular
localization
and
active
involvement
gene
regulation
chromatin
remodeling.
The
highlights
impact
on
LC
development
progression,
including
cell
processes
such
as
proliferation,
migration,
invasion,
resistance
to
therapy,
positioning
it
a
potential
diagnostic
marker
therapeutic
target.
complex
web
regulatory
interactions
with
proteins
microRNAs
is
explored,
alongside
challenges
targeting
therapeutically.
concludes
optimistically,
suggesting
future
avenues
for
research
personalized
therapies,
shedding
light
crucial
LC.
See
also
Graphical
abstract(Fig.
1).
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2024,
Номер
43(1)
Опубликована: Март 16, 2024
Abstract
The
paradigm
of
non-small
cell
lung
cancer
(NSCLC)
treatment
has
been
profoundly
influenced
by
the
development
immune
checkpoint
inhibitors
(ICI),
but
range
clinical
responses
observed
among
patients
poses
significant
challenges.
To
date,
analyses
tumor
biopsies
are
only
parameter
used
to
guide
prognosis
ICI
therapy.
Tumor
biopsies,
however,
often
difficult
obtain
and
tissue-based
biomarkers
limited
intratumoral
heterogeneity
temporal
variability.
In
response,
there
a
growing
emphasis
on
“liquid
biopsy”‒
derived
biomarkers,
which
offer
minimally
invasive
means
dynamically
monitor
status
NSCLC
either
before
and/or
during
course
treatment.
Here
we
review
studies
in
multiple
blood-based
encompassing
circulating
soluble
analytes,
subsets,
DNA,
mutational
burden,
cells
have
shown
promising
associations
with
response
These
investigations
unveiled
compelling
correlations
between
peripheral
both
therapy
patient
outcomes,
include
rates,
progression-free
survival,
overall
survival.
There
is
need
for
rigorous
validation
standardization
these
assays
broader
application.
Integration
into
comprehensive
panels
or
algorithms
also
potential
enhance
predictive
accuracy.
Further
research
aimed
at
longitudinal
monitoring
crucial
comprehend
dynamics
resistance
mechanisms
should
be
alongside
methods
that
interrogate
microenvironment
decisions
may
inform
novel
therapeutic
strategies.
data
reviewed
here
reinforce
opportunity
refine
stratification,
optimize
treatments,
improve
outcomes
not
wider
spectrum
solid
tumors
undergoing
immunotherapy.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(14), С. 4189 - 4189
Опубликована: Июль 18, 2024
The
leading
cause
of
cancer
deaths
worldwide
is
attributed
to
non-small
cell
lung
(NSCLC),
necessitating
a
continual
focus
on
improving
the
diagnosis
and
treatment
this
disease.
In
review,
latest
breakthroughs
emerging
trends
in
managing
NSCLC
are
highlighted.
Major
advancements
diagnostic
methods,
including
better
imaging
technologies
utilization
molecular
biomarkers,
discussed.
These
have
greatly
enhanced
early
detection
personalized
plans.
Significant
improvements
patient
outcomes
been
achieved
by
new
targeted
therapies
immunotherapies,
providing
hope
for
individuals
with
advanced
NSCLC.
This
review
discusses
persistent
challenges
accessing
treatments
their
associated
costs
despite
recent
progress.
Promising
research
into
therapies,
such
as
CAR-T
therapy
oncolytic
viruses,
which
could
further
revolutionize
treatment,
also
aims
inform
inspire
continued
efforts
improve
patients
globally,
offering
comprehensive
overview
current
state
future
possibilities.
Cells,
Год журнала:
2024,
Номер
13(5), С. 436 - 436
Опубликована: Март 1, 2024
Lung
cancer
remains
a
formidable
global
health
challenge
that
necessitates
inventive
strategies
to
improve
its
therapeutic
outcomes.
The
conventional
treatments,
including
surgery,
chemotherapy,
and
radiation,
have
demonstrated
limitations
in
achieving
sustained
responses.
Therefore,
exploring
novel
approaches
encompasses
range
of
interventions
show
promise
enhancing
the
outcomes
for
patients
with
advanced
or
refractory
cases
lung
cancer.
These
groundbreaking
can
potentially
overcome
resistance
offer
personalized
solutions.
Despite
rapid
evolution
emerging
therapies,
persistent
challenges
such
as
resistance,
toxicity,
patient
selection
underscore
need
continued
development.
Consequently,
landscape
therapy
is
transforming
introduction
precision
medicine,
immunotherapy,
innovative
modalities.
Additionally,
multifaceted
approach
involving
combination
therapies
integrating
targeted
agents,
immunotherapies,
traditional
cytotoxic
treatments
addresses
heterogeneity
while
minimizing
adverse
effects.
This
review
provides
brief
overview
latest
are
reshaping
treatment.
As
these
progress
through
clinical
trials
integrated
into
standard
care,
potential
more
effective,
targeted,
comes
focus,
instilling
renewed
hope
facing
challenging
diagnoses.
Cancers,
Год журнала:
2024,
Номер
16(13), С. 2338 - 2338
Опубликована: Июнь 26, 2024
Non-small-cell
lung
cancer
(NSCLC)
comprises
approximately
85%
of
all
cases,
often
diagnosed
at
advanced
stages,
which
diminishes
the
effective
treatment
options
and
survival
rates.
This
systematic
review
assesses
utility
emerging
biomarkers-circulating
tumor
DNA
(ctDNA),
microRNAs
(miRNAs),
blood
mutational
burden
(bTMB)-enhanced
by
next-generation
sequencing
(NGS)
to
improve
diagnostic
accuracy,
prognostic
evaluation,
strategies
in
NSCLC.
Analyzing
data
from
37
studies
involving
10,332
patients
2020
2024,
highlights
how
biomarkers
like
ctDNA
PD-L1
expression
critically
inform
selection
personalized
therapies,
particularly
beneficial
stages
These
are
critical
for
assessments
dynamically
adapting
plans,
where
high
specific
genetic
mutations
(e.g.,
ALK
fusions,
EGFR
mutations)
significantly
guide
use
targeted
therapies
immunotherapies.
The
findings
recommend
integrating
these
into
standardized
clinical
pathways
maximize
their
potential
enhancing
precision,
ultimately
fostering
significant
advancements
oncology
improving
patient
outcomes
quality
life.
substantiates
predictive
value
emphasizes
need
ongoing
innovation
biomarker
research.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(14), С. 7530 - 7530
Опубликована: Июль 9, 2024
Aging
is
a
multifaceted
process
influenced
by
hereditary
factors,
lifestyle,
and
environmental
elements.
As
time
progresses,
the
human
body
experiences
degenerative
changes
in
major
functions.
The
external
internal
signs
of
aging
manifest
various
ways,
including
skin
dryness,
wrinkles,
musculoskeletal
disorders,
cardiovascular
diseases,
diabetes,
neurodegenerative
cancer.
Additionally,
cancer,
like
aging,
complex
disease
that
arises
from
accumulation
genetic
epigenetic
alterations.
Circadian
clock
dysregulation
has
recently
been
identified
as
an
important
risk
factor
for
cancer
development.
Natural
compounds
herbal
medicines
have
gained
significant
attention
their
potential
preventing
age-related
diseases
inhibiting
progression.
These
demonstrate
antioxidant,
anti-inflammatory,
anti-proliferative,
pro-apoptotic,
anti-metastatic,
anti-angiogenic
effects
well
circadian
regulation.
This
review
explores
cancers,
specific
natural
targeting
key
features
these
conditions.
Clinical and Experimental Medicine,
Год журнала:
2025,
Номер
25(1)
Опубликована: Янв. 11, 2025
IL-27
is
structurally
an
immune-enhancing
and
pleiotropic
two-chain
cytokine
associated
with
IL-12
IL-6
families.
contains
two
subunits,
namely
IL-27p28
EBI3.
A
heterodimer
receptor
of
IL-27,
composed
IL27Rα
(WSX1)
IL6ST
(gp130)
chains,
mediates
the
function
following
activation
STAT1
STAT3
signaling
pathways.
Specifically,
identified
as
augmenting
immune
responses,
including
Th1
cell
differentiation,
TCd4
+
proliferation,
IFN-γ
production
help
IL-12.
According
to
several
published
studies,
due
pro-inflammatory
or
anti-inflammatory
functions
related
biological
context
in
various
disorders
diseases,
has
been
considered
a
complex
regulator
system.
Surprisingly,
dual
role
same
double-edged
sword,
also
evidenced
clinical
models
hematological
solid
tumors.
Predominantly,
Il-27
applies
anti-tumor
by
inducing
responses
cytotoxic
T
lymphocyte
(CTL)
suppressing
growth,
angiogenesis,
invasiveness,
metastasis,
survival
tumor
cells.
On
other
hand,
may
play
protumor
cancers
induce
progression.
The
current
update
study
aimed
summarize
different
malignancies
